Paige receives marks for breast lymph node AI software

By LabPulse.com staff writers

April 8, 2022 -- Artificial intelligence (AI) developer Paige recently received CE-in vitro diagnostic (CE-IVD) and U.K. Conformity Assessed (UKCA) marks for its Paige Breast Lymph Node.

The AI medical device software helps pathologists detect if breast cancer has metastasized to lymph nodes along with review by pathologists.

With the latest marks, laboratories and hospitals in the European Economic Area, Switzerland, and the U.K. can now use the software for clinical diagnosis applications.

Ultivue, Paige partner to advance AI products
Boston-based biomarker assay developer Ultivue and artificial intelligence (AI) software developer Paige have established a collaborative agreement to...
Paige unveils breast lymph node software at USCAP 2022
Artificial intelligence-based software developer Paige unveiled its breast lymph node application at this week's United States and Canadian Academy of...
Paige links with Flagship on biomarker analysis tools
Pathology artificial intelligence software developer Paige has inked a partnership with Flagship Biosciences that makes Flagship's diagnostics software...
Paige partners with Mindpeak for AI breast cancer software
Paige and Mindpeak have announced a distribution partnership that will enable pathologists to use Mindpeak's BreastIHC artificial intelligence (AI) software...
Paige appoints new executives
Artificial intelligence software developer Paige announced that it has appointed new executive leaders, including Andy Moye, PhD, as CEO and Jill Stefanelli,...

Copyright © 2022 LabPulse.com

Last Updated 4/8/2022 1:44:43 PM